Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cogent Biosciences, Inc. - Common Stock (NQ:COGT)

31.02 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	462
Open	31.02
Bid (Size)	31.00 (100)
Ask (Size)	33.50 (200)
Prev. Close	31.02
Today's Range	31.02 - 31.02
52wk Range	6.590 - 43.73
Shares Outstanding	85,465,249
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.

Via The Motley Fool

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗

May 23, 2026

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.

Via The Motley Fool

Performance

YTD	-10.7%	-10.7%
1 Month	-10.7%	-10.7%
3 Month	-16.2%	-16.2%
6 Month	-23.0%	-23.0%
1 Year	+349.6%	+349.6%

More News

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗

May 23, 2026

Via The Motley Fool

Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores ↗

May 02, 2026

Via Chartmill

What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗

May 18, 2026

Via The Motley Fool

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗

May 18, 2026

Via The Motley Fool

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Via The Motley Fool

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗

May 17, 2026

Via The Motley Fool

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗

May 17, 2026

Via The Motley Fool

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗

May 17, 2026

Via The Motley Fool

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

Via The Motley Fool

The Great Rotation of 2026: Why Small Caps are Finally Dethroning the Tech Giants

March 27, 2026

Via MarketMinute

The Great Rotation: Small-Caps Seize Market Leadership in Historic 2026 Breakout

March 25, 2026

Via MarketMinute

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Via The Motley Fool

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

Via The Motley Fool

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

Via The Motley Fool

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

Via The Motley Fool

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗

March 18, 2026

Via The Motley Fool

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗

March 18, 2026

Via The Motley Fool

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗

March 18, 2026

Via The Motley Fool

This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗

March 18, 2026

Via The Motley Fool

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗

March 13, 2026

Via The Motley Fool

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗

March 13, 2026

Via The Motley Fool

Frequently Asked Questions

Is Cogent Biosciences, Inc. - Common Stock publicly traded?

Yes, Cogent Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Cogent Biosciences, Inc. - Common Stock trade on?

Cogent Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cogent Biosciences, Inc. - Common Stock?

The ticker symbol for Cogent Biosciences, Inc. - Common Stock is COGT on the Nasdaq Stock Market

What is the current price of Cogent Biosciences, Inc. - Common Stock?

The current price of Cogent Biosciences, Inc. - Common Stock is 31.02

When was Cogent Biosciences, Inc. - Common Stock last traded?

The last trade of Cogent Biosciences, Inc. - Common Stock was at 06/05/26 04:00 PM ET

What is the market capitalization of Cogent Biosciences, Inc. - Common Stock?

The market capitalization of Cogent Biosciences, Inc. - Common Stock is 2.65B

How many shares of Cogent Biosciences, Inc. - Common Stock are outstanding?

Cogent Biosciences, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.